BioRestorative Therapies, Inc.
BRTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.03 | -0.00 | -0.03 |
| FCF Yield | -21.95% | -18.46% | -18.92% | -21.26% |
| EV / EBITDA | -4.23 | -5.01 | -2.87 | -4.00 |
| Quality | ||||
| ROIC | -168.06% | -68.22% | -78.24% | -31.53% |
| Gross Margin | -435.51% | 97.12% | 88.36% | 92.29% |
| Cash Conversion Ratio | 0.95 | 1.01 | 0.52 | 1.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 43.33% | 67.62% | 42.51% | 49.59% |
| Free Cash Flow Growth | -7.69% | 4.31% | -19.27% | -34.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 0.60 | 0.26 | 0.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,122.55 | -6,284.22 | -18,457.61 | -12,629.16 |